Παρατίθεται απόσπασμα της συνέντευξης της Στέλλας Κυριακίδoυ στους Financial times, Η κυρία Κυριακίδου, είναι πό το 2019 είναι Επίτροπος Υγείας και Ασφάλειας Τροφίμων της Ευρωπαϊκής Ένωσης.
Η ουσία στέκεται σε μια φράση που ο δικός μας Βασίλης (ο εκ του Βόλου ορμώμενος) είχε αναφέρει αρκετά πριν, στο λάθος της ΕΕ, σε ότι είναι απλά "φθηνό", με ιδιαίτερη έμφαση , στον τομέα των φαρμάκων , και κατ'επέκταση και σε άλλα παραφαρμακευτικά είδη όπως οι χειρουργικές μάσκες,που οδήγησε την αγορά στο μονοπώλιο της Κίνας και κατ επέκταση της Ινδίας. Το πρώτο καμπανάκι ήρθε με τον δεκαπλασιασμό της χονδρικής τιμής και της έλλειψης φαρμάκων όπως τα σιρόπια παρακεταμόλης, στην έναρξη της πανδημίας.
source
https://www.ft.com/content/c30eb13a-f49e-4d42-b2a8-1c6f70bb4d55
In response to the health crisis that has heightened tensions in the single market and laid bare an overdependence on China and India for some life-saving pharmaceuticals, Stella Kyriakides called for “more Europe in the area of public health”. “Fragmentation makes us more vulnerable. We need to pool resources, if we don’t pool resources we are weaker,” Ms Kyriakides said in an interview with the Financial Times on Monday. “There is now a realisation that nobody can deal with this public health crisis alone.” The lessons from the coronavirus outbreak will loom large in an EU pharmaceuticals strategy due to be outlined later this year and a “Conference on the Future of Europe” announced by EU leaders before the pandemic took hold. The commissioner said Brussels would use its pharmaceuticals strategy to tackle supply chain problems revealed by the crisis, notably the bloc’s reliance on China and India for imports of crucial intensive care drugs including narcotic pain relievers, muscle relaxant ingredients and some older anaesthetics. A paper prepared for the EU pharmaceutical committee last month suggested as much as 90 per cent of active pharmaceutical ingredients (APIs) for generic medicines were sourced from India and China. Stella Kyriakides wants ‘more Europe in the area of public health’ © Olivier Hoslet/EPA-EFE “The issue of dependency of the EU vis-à-vis China, and other countries . . . was on the table before Covid-19,” said Ms Kyriakides, one of the most high-profile figures in Brussels’ pandemic response. “[The crisis] has highlighted this problem and we need to look at it, we need to ensure that we reduce our dependency on other countries.” Brussels’ goal would not be “total autonomy” of supply but to “have proposals that would encourage industry and production again within the EU”, she said. Ms Kyriakides, a Cypriot psychologist and politician who took up her post in December, also urged member states to lift their export restrictions on medicines. The commission has threatened possible legal action if they refuse to do so. The European Federation of Pharmaceutical Industries and Associations — EFPIA — warned on Sunday that such “restrictions and requisitioning of medicines continue to exist across the EU in countries such as Belgium, Hungary, or Portugal”. The commissioner said she had spoken to EFPIA on Friday and was working to get the “really not acceptable” restrictions lifted. “I have sent letters to member states, urging them to lift their export restrictions — 15 letters so far,” she said. “We have been very clear with them that we will not hesitate to use our enforcement powers through infringement procedures if necessary, to ensure the smooth functioning of the internal market.” European Commission president Ursula von der Leyen has slammed the EU’s political fragmentation, exposed during the opening phase of the coronavirus pandemic, when European countries closed their borders and tightened medical equipment export rules. Last week she issued a “heartfelt apology” to Italy over the failure of fellow member states to help the country — the first in Europe to be crippled by coronavirus — when the outbreak began. Brussels has successfully pressured France and Germany to modify export restrictions, and secured the creation of priority “green lanes” to allow vital equipment to cross the continent without becoming snarled up in tailbacks caused by extra border controls. It has launched joint procurement for crucial items such as ventilators, and has set up a clearing house aimed at ensuring medical equipment goes where it is most needed. But Ms Kyriakides said there was still a mismatch that had to be dealt with between the EU’s limited legal powers in the area of public health and the expectations of citizens for Brussels to act to protect them. “We have the opportunity with the process that will be starting with the Conference on the Future of Europe to start this discussion,” she said. “This is a discussion that needs to be addressed and needs to be open.” The conference, a structured series of citizens’ debates on the EU’s future priorities, was due to begin in May and last for two years. Those plans are now on hold because of the pandemic.
https://www.ft.com/content/c30eb13a-f49e-4d42-b2a8-1c6f70bb4d55
In response to the health crisis that has heightened tensions in the single market and laid bare an overdependence on China and India for some life-saving pharmaceuticals, Stella Kyriakides called for “more Europe in the area of public health”. “Fragmentation makes us more vulnerable. We need to pool resources, if we don’t pool resources we are weaker,” Ms Kyriakides said in an interview with the Financial Times on Monday. “There is now a realisation that nobody can deal with this public health crisis alone.” The lessons from the coronavirus outbreak will loom large in an EU pharmaceuticals strategy due to be outlined later this year and a “Conference on the Future of Europe” announced by EU leaders before the pandemic took hold. The commissioner said Brussels would use its pharmaceuticals strategy to tackle supply chain problems revealed by the crisis, notably the bloc’s reliance on China and India for imports of crucial intensive care drugs including narcotic pain relievers, muscle relaxant ingredients and some older anaesthetics. A paper prepared for the EU pharmaceutical committee last month suggested as much as 90 per cent of active pharmaceutical ingredients (APIs) for generic medicines were sourced from India and China. Stella Kyriakides wants ‘more Europe in the area of public health’ © Olivier Hoslet/EPA-EFE “The issue of dependency of the EU vis-à-vis China, and other countries . . . was on the table before Covid-19,” said Ms Kyriakides, one of the most high-profile figures in Brussels’ pandemic response. “[The crisis] has highlighted this problem and we need to look at it, we need to ensure that we reduce our dependency on other countries.” Brussels’ goal would not be “total autonomy” of supply but to “have proposals that would encourage industry and production again within the EU”, she said. Ms Kyriakides, a Cypriot psychologist and politician who took up her post in December, also urged member states to lift their export restrictions on medicines. The commission has threatened possible legal action if they refuse to do so. The European Federation of Pharmaceutical Industries and Associations — EFPIA — warned on Sunday that such “restrictions and requisitioning of medicines continue to exist across the EU in countries such as Belgium, Hungary, or Portugal”. The commissioner said she had spoken to EFPIA on Friday and was working to get the “really not acceptable” restrictions lifted. “I have sent letters to member states, urging them to lift their export restrictions — 15 letters so far,” she said. “We have been very clear with them that we will not hesitate to use our enforcement powers through infringement procedures if necessary, to ensure the smooth functioning of the internal market.” European Commission president Ursula von der Leyen has slammed the EU’s political fragmentation, exposed during the opening phase of the coronavirus pandemic, when European countries closed their borders and tightened medical equipment export rules. Last week she issued a “heartfelt apology” to Italy over the failure of fellow member states to help the country — the first in Europe to be crippled by coronavirus — when the outbreak began. Brussels has successfully pressured France and Germany to modify export restrictions, and secured the creation of priority “green lanes” to allow vital equipment to cross the continent without becoming snarled up in tailbacks caused by extra border controls. It has launched joint procurement for crucial items such as ventilators, and has set up a clearing house aimed at ensuring medical equipment goes where it is most needed. But Ms Kyriakides said there was still a mismatch that had to be dealt with between the EU’s limited legal powers in the area of public health and the expectations of citizens for Brussels to act to protect them. “We have the opportunity with the process that will be starting with the Conference on the Future of Europe to start this discussion,” she said. “This is a discussion that needs to be addressed and needs to be open.” The conference, a structured series of citizens’ debates on the EU’s future priorities, was due to begin in May and last for two years. Those plans are now on hold because of the pandemic.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου